A basic metabolic panel comes back and one line is flagged, slightly high, no other symptoms. The waste product in question is uric acid, and it carries an unusual distinction: humans run higher levels of it than almost any other mammal, for a reason written into our genome millions of years before anyone had a joint flare or a kidney stone. Understanding that backstory changes how the number reads.
What uric acid actually is
Uric acid is a normal waste product your body makes when it breaks down purines, compounds released when cells die and also found in certain foods and drinks. Normally, uric acid dissolves in the blood, passes through the kidneys, and leaves the body in urine. When the body makes too much or the kidneys clear too little, it builds up and can form sharp, needle-shaped crystals in and around the joints, a condition called gout, a painful form of arthritis. The same crystals can also build up in the kidneys and form kidney stones.
Reference ranges vary by lab and by sex. MedlinePlus and UCSF Health cite a general adult range of roughly 3.5 to 7.2 mg/dL, while other labs report separate bands for women (about 1.5 to 6.0 mg/dL) and men (about 2.5 to 7.0 mg/dL). Hyperuricemia, the term for a high level, is generally defined as above 6.0 mg/dL in women and above 7.0 mg/dL in men. There is a physical reason that particular line matters: urate, the form uric acid takes in the body, saturates in body fluids at around 6.8 mg/dL. Above that point, crystals can begin to form. It is not a bright line so much as a solubility limit, but it is the closest thing this test has to a mechanistic threshold rather than a population-based cutoff.
Cleveland Clinic notes that hyperuricemia is common: about one in five people has it, and roughly 5% of people in the United States have gout, with men about four times more likely than women to develop it. Crucially, having a high level does not guarantee symptoms. Hyperuricemia itself usually causes nothing on its own; most people find out only when a gout attack or a kidney stone announces it.
A level other mammals don't carry
Most mammals keep uric acid low with the help of an enzyme called uricase, which breaks it down further into a compound the kidneys clear easily. Humans, along with the other great apes, don't have a working copy of that gene. Research led by physician-scientist Richard Johnson and colleagues, along with ancestral-protein studies published in the Proceedings of the National Academy of Sciences, traces the loss to a series of mutations in the mid-to-late Miocene epoch, roughly 15 to 20 million years ago. The result is that humans and apes carry uric acid levels in the range of 3 to 7 mg/dL, while most other mammals run below 1 to 2 mg/dL.
The leading explanation is known as the thrifty gene hypothesis, though here it is the loss of a gene rather than the gain of one. Early apes lived largely on fruit, rich in fructose. Researchers studying resurrected ancestral versions of the uricase enzyme found that a less active uricase let liver cells convert fructose into fat more readily, a plausible advantage as the Miocene's global cooling shrank the fruit-bearing rainforests these apes depended on. Higher uric acid may also have worked as an antioxidant and helped preserve blood pressure under low-salt conditions. Notably, humans separately lost the ability to synthesize their own vitamin C around a similar window of primate evolution, and some of the same researchers argue the two losses share the same fructose-driven survival logic. Whatever the mix of pressures, the legacy is a baseline uric acid higher than most of the animal kingdom's, one that stays unusually responsive to diet, particularly fructose, alcohol, and purine-rich foods like organ meats and certain seafood.
The unresolved argument: marker or driver
This is where uric acid research gets genuinely contested, and where it earns a place alongside other markers whose evidence turned out messier than their reputation. Higher uric acid tracks consistently with hypertension, insulin resistance, fatty liver disease, and metabolic syndrome in observational studies. Cleveland Clinic lists high blood pressure, diabetes, kidney disease, and fatty liver disease among the conditions linked to elevated levels. Some researchers, including Johnson's group, argue this is more than correlation: animal studies show that blocking uricase raises uric acid and produces hypertension, and a well-designed randomized trial in adolescents with newly diagnosed high blood pressure found that four weeks of the uric-acid-lowering drug allopurinol dropped systolic blood pressure by roughly 7 mm Hg compared with placebo, a substantial effect for a short trial.
But the picture gets murkier in adults and in larger studies. A systematic review and meta-analysis of ten clinical studies found allopurinol lowered systolic blood pressure by only about 3 mm Hg on average, real but modest. A Mendelian randomization study, a method that uses genetic variation to test for causation, found no consistent evidence that genetically higher uric acid causally raises blood pressure or cardiovascular risk, suggesting some of allopurinol's benefit might come from its antioxidant properties rather than from lowering uric acid itself. A 2026 randomized trial in healthy kidney donors found allopurinol lowered uric acid substantially but changed nothing about blood pressure, heart mass, or insulin sensitivity. The honest summary, echoed in a 2023 review of the trial evidence, is that decades of association have not settled into a clear verdict: uric acid may genuinely contribute to cardiovascular and metabolic disease in some people, or it may largely be a bystander rising alongside the same insulin resistance and kidney strain that cause the real damage. Major guideline bodies, including the Joint National Committee, still do not classify uric acid as an established, independent cardiovascular risk factor.
What this means for reading your own number
None of this uncertainty changes the two things a uric acid test is genuinely good at: helping diagnose gout alongside a joint fluid analysis, and monitoring people at risk of kidney stones or those undergoing cancer treatments that rapidly release purines into the blood. For an asymptomatic high result outside those situations, most guidance, including Cleveland Clinic's, is to treat it as a data point worth tracking and a nudge toward diet and hydration rather than an automatic prescription. Purine-rich foods (red meat, organ meats, certain shellfish), alcohol, and drinks sweetened with high-fructose corn syrup are the levers with the most consistent evidence behind them.
Common questions
What counts as a high uric acid level?
Reference ranges vary by lab, but hyperuricemia is generally defined as above 6.0 mg/dL in women and above 7.0 mg/dL in men, close to the roughly 6.8 mg/dL point at which urate begins to saturate body fluids and crystals can form.
Does having high uric acid mean I'll develop gout?
No. Hyperuricemia is common, affecting about one in five people, while gout affects roughly 5% of the U.S. population. Many people carry elevated uric acid for years without a single gout attack, and diagnosis of gout itself requires finding crystals in joint fluid, not just a high blood number.
Why do humans have higher uric acid than most other animals?
Humans and the other great apes lost a working copy of the uricase gene, the enzyme most mammals use to break uric acid down further, in a series of mutations roughly 15 to 20 million years ago. The leading hypothesis is that higher uric acid helped early fruit-eating apes convert dietary fructose into stored fat, an advantage when food supply became less reliable.
Can diet actually lower uric acid?
Yes, modestly. Limiting red meat, organ meats, certain seafood, alcohol, and high-fructose-corn-syrup beverages, along with staying well hydrated, are the changes with the most consistent support, according to Cleveland Clinic and MedlinePlus.
Does lowering uric acid with medication improve blood pressure or heart health?
The evidence is mixed. Some trials, particularly in adolescents and younger patients, have shown meaningful blood pressure reductions from urate-lowering drugs like allopurinol. Larger and more rigorous studies, including a 2026 randomized trial in kidney donors and genetic Mendelian randomization analyses, have found little to no effect, leaving the question of causation unresolved.
